Gain of function mutation of the α7 nicotinic receptor: Distinct pharmacology of the human α7V274T variant

European Journal of Pharmacology

Volumn 366, Issue 2-3, 1999, Pages 301-308

  Briggs, Clark A ^a   McKenna, David G ^a   Monteggia, Lisa M ^a   Touma, Edward ^a   Roch, Jean Marc ^a   Arneric, Stephen P ^a   Gopalakrishnan, Murali ^a   Sullivan, James P ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Dihydro erythroidine; Human; Mecamylamine; Methyllycaconitine; Nicotinic receptor; Oocyte, Xenopus laevis

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ACETYLCHOLINE; MECAMYLAMINE; METHYLLYCACONITINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENE MUTATION; NONHUMAN; OOCYTE; PRIORITY JOURNAL;

ACETYLCHOLINE; ACONITINE; AMINO ACID SUBSTITUTION; ANIMALS; ATROPINE; CHOLINE; DIHYDRO-BETA-ERYTHROIDINE; DIMETHYLPHENYLPIPERAZINIUM IODIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOBELINE; MECAMYLAMINE; MEMBRANE POTENTIALS; MUSCARINIC ANTAGONISTS; MUTATION; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; OOCYTES; PYRIDINES; PYRROLIDINES; RECEPTORS, NICOTINIC; THREONINE; TUBOCURARINE; VALINE; VARIATION (GENETICS); XENOPUS;

EID: 0033030490     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00909-1     Document Type: Article

References (40)

1. Benowitz N.L. Pharmacology of nicotine: addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 36:1996;597-613.
2. Bertrand D., Changeux J.-P. Nicotinic receptor: an allosteric protein specialized for intercellular communication. Sem. Neurosci. 7:1995;75-90.
3. Bertrand D., Devillers-Thiéry A., Revah F., Galzi J.-L., Hussy N., Mulle C., Bertrand S., Ballivet M., Changeux J.-P. Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain. Proc. Natl. Acad. Sci. USA. 89:1992;1261-1265.
4. Bertrand S., Devillers-Thiéry A., Palma E., Buisson B., Edelstein S.J., Corringer P.-J., Changeux J.P., Bertrand D. Paradoxical allosteric effects of competitive inhibitors on neuronal α7 nicotinic receptor mutants. NeuroReport. 8:1997;3591-3596.
5. Bouzat C., Roccamo A.M., Garbus I., Barrantes F.J. Mutations at lipid-exposed residues of the acetylcholine-receptor affect its gating kinetics. Mol. Pharmacol. 54:1998;146-153.
6. Briggs C.A., McKenna D.G. Effect of MK-801 at the human α7 nicotinic acetylcholine receptor. Neuropharmacology. 35:1996;407-414.
7. Briggs C.A., McKenna D.G. Activation and inhibition of the human α7 nicotinic acetylcholine receptor by agonists. Neuropharmacology. 37:1998;1095-1102.
8. Briggs C.A., McKenna D.G., Piattoni-Kaplan M. Human α7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology. 34:1995;583-590.
9. Croxen R., Newland C., Beeson D., Oosterhuis H., Chauplannaz G., Vincent A., Newsom-Davis J. Mutations in different functional domains of the human muscle acetylcholine receptor α-subunit in patients with the slow channel congenital myasthenic syndrome. Hum. Mol. Genet. 6:1997;767-774.
10. Dascal N., Landau E.M. Types of muscarinic response in Xenopus oocytes. Life Sci. 27:1980;1423-1428.
11. 125I -α-bungarotoxin receptor subtypes Mol. Pharmacol. 47:1995;164-171.
12. Devillers-Thiéry A., Galzi J.L., Bertrand S., Changeux J.-P., Bertrand D. Stratified organization of the nicotinic acetylcholine receptor channel. NeuroReport. 3:1992;1001-1004.
13. Doucette-Stamm L., Monteggia L.M., Donnelly-Roberts D., Wang M.T., Lee J., Tian J., Giordano T. Cloning and sequence of the human α7 nicotinic acetylcholine receptor. Drug Dev. Res. 30:1993;252-256.
14. Edelstein S.J., Changeux J.P. Allosteric proteins after thirty years: the binding and state functions of the neuronal α7 nicotinic acetylcholine receptors. Experientia. 52:1996;1083-1090.
15. Elliott K., Urrutia A., Johnson E., Williams M.E., Ellis S.B., Velicelebi G., Harpold M.M. Cloning and functional expression of human neuronal nicotinic acetylcholine receptor subunits α2, α3, α4, α7, β2 and β4. Soc. Neurosci. Abstr. 19:1993;69.
16. Engel, A.G., Ohno, K., Wang, H.L., Milone, M., Sine, S.M., 1998. Molecular basis of congenital myasthenic syndromes: mutations in the acetylcholine receptor. Neuroscientist, 185-194.
17. Forster I., Bertrand D. Inward rectification of neuronal nicotinic acetylcholine receptors investigated by using the homomeric α7 receptor. Proc. R. Soc. London. 260:1995;139-148.
18. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA. 94:1997;587-592.
19. Galzi J.-L., Devillers-Thiéry A., Hussy N., Bertrand S., Changeux J.-P., Bertrand D. Mutations in the channel domain of a neuronal nicotinic receptor convert ion selectivity from cationic to anionic. Nature. 359:1992;500-505.
20. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 77:1989;51-59.
21. 2+ permeability, conductance, and gating of human α4β2 nicotinic acetylcholine receptors. J. Neurosci. 17:1997;9035-9047.
22. Labarca C., Nowak M.W., Zhang H.Y., Tang L.X., Deshpande P., Lester H.A. Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors. Nature. 376:1995;514-516.
23. Lin N.H., Gunn D.E., Ryther K.B., Garvey D.S., Donnelly-Roberts D.L., Decker M.W., Brioni J.D., Buckley M.J., Rodrigues A.D., Marsh K.C., Anderson D.J., Buccafusco J.J., Prendergast M.A., Sullivan J.P., Williams M., Arneric S., Holladay M.W. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J. Med. Chem. 40:1997;385-390.
24. Lynch J.W., Rajendra S., Pierce K.D., Handford C.A., Barry P.H., Schofield P.R. Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel. EMBO J. 16:1997;110-120.
25. McKenna D.G., Monteggia L.M., Touma E., Gopalakrishnan M., Roch J.-M., Arneric S.P., Sullivan J.P., Briggs C.A. Gain of function mutation of human α7 nAChR: distinct pharmacology of h-α7V274T. Soc. Neurosci. Abstr. 23:1997;156.16.
26. Ortiz-Miranda S.I., Lasalde J.A., Pappone P.A., McNamee M.G. Mutations in the M4 domain of the Torpedo californica nicotinic acetylcholine receptor alter channel opening and closing. J. Membr. Biol. 158:1997;17-30.
27. Palma E., Eusebi F., Miledi R. Coexpression of the neuronal α7 and L247T α7 mutant subunits yields hybrid nicotinic receptors with properties of both wild-type α7 and α7 mutant homomeric receptors. Proc. Natl. Acad. Sci. USA. 94:1997;1539-1543.
28. Pan Z.H., Zhang D.X., Zhang X.S., Lipton S.A. Agonist-induced closure of constitutively open γ-aminobutyric acid channels with mutated M2 domains. Proc. Natl. Acad. Sci. USA. 94:1997;6490-6495.
29. Papke R.L., Bencherif M., Lippiello P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the α7 subtype. Neurosci. Lett. 213:1996;201-204.
30. Peng X., Katz M., Gerzanich V., Anand R., Lindstrom J. Human α7 acetylcholine receptor: cloning of the α7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and function α7 homomers expressed in Xenopus oocytes. Mol. Pharmacol. 45:1994;546-554.
31. Revah F., Bertrand D., Galzi J.-L., Devillers-Thiéry A., Mulle C., Hussy N., Bertrand S., Ballivet M., Changeux J.-P. Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature. 353:1991;846-849.
32. Steinlein O.K., Magnusson A., Stoodt J., Bertrand S., Weiland S., Berkovic S.F., Nakken K.O., Propping P., Bertrand D. An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy. Hum. Mol. Genet. 6:1997;943-947.
33. Unwin N. The nicotinic acetylcholine receptor of the Torpedo electric ray. Journal of Structural Biology. 121:1998;181-190.
34. A, and nicotinic acetylcholine receptors provide new insights into the ligand-gated ion channel receptor superfamily. Int. Rev. Neurobiol. 42:1998;285-332.
35. Wang H.L., Auerbach A., Bren N., Ohno K., Engel A.G., Sine S.M. Mutation in the M1 domain of the acetylcholine receptor α subunit decreases the rate of agonist dissociation. J. Gen. Physiol. 109:1997;757-766.
36. Weiland S., Witzemann V., Villarroel A., Propping P., Steinlein O. An amino acid exchange in the 2nd transmembrane segment of a neuronal nicotinic receptor causes partial epilepsy by altering its desensitization kinetics. FEBS Lett. 398:1996;91-96.
37. Yakel J.L., Lagrutta A., Adelman J.P., North R.A. Single amino acid substitution affects desensitization of the 5-hydroxytryptamine type 3 receptor expressed in Xenopus oocytes. Proc. Natl. Acad. Sci. USA. 90:1993;5030-5033.
38. Zhang H., Karlin A. Identification of acetylcholine receptor channel lining residues in the M1 segment of the β-subunit. Biochemistry. 36:1997;15856-15864.
39. Zhang H.-G., Ffrench-Constant R.H., Jackson M.B. A unique amino acid of the Drosophila GABA receptor with influence on drug sensitivity by two mechanisms. J. Physiol. (London). 479:1994;65-75.
40. Zoltewicz J.A., Prokai-Tatrai K., Bloom L.B., Kem W.R. Long range transmission of polar effects in cholinergic 3-arylidene anabaseines. Conformations calculated by molecular modeling. Heterocycles. 35:1993;171-179.